Manufacturing and Formulation Solutions for Inhaled Dose Forms

Sponsored Content

Catalent combines its formulation expertise, manufacturing excellence and particle size reduction technologies to provide a broad range of solutions in the development of inhalation and nasal drug products.

Catalent Pharma Solutions, the leading global provider of advanced drug delivery technologies and development, provides a broad range of inhalation solutions.

 

From pre-formulation to commercialisation, Catalent integrates its experience in pre-formulation sciences, formulation development, device evaluation/selection, performance testing, chemistry, manufacturing and control (CMC), and manufacturing to reliably deliver dosage forms including:

 

   •   Pressurized metered dose inhalers (pMDIs)
   •   Dry powder inhaler (DPIs)
   •   Nasal sprays
   •   Solutions/suspensions for inhalation.

 

 

The integration of Catalent Micron’s particle size reduction capabilities into the company’s development and formulation portfolio provides unique solutions in micronisation and classification of powders, meeting the tightest specifications required for inhalation products. These include:

 

   •   Micronisation (jet mill)
   •   Mechanical milling (hammer mill, pin mill)
   •   Cryogenic milling
   •   Potent and cytotoxic compounds
   •   Comprehensive analytical services.

 

For more than 40 years, Catalent has provided end-to-end solutions from its inhalation manufacturing operations in RTP, North Carolina, and Woodstock, Illinois. The deep expertise in this specialised field, and reliable execution have been successfully applied to all primary inhaled dosage forms to accelerate drug development programmes and bring better treatments to patients worldwide.